Drug Profile
Sargramostim companion diagnostic - Biomedical Advanced Research and Development Authority/Labcorp Drug Development/Partner Therapeutics
Alternative Names: HLA-DR companion diagnostic - Biomedical Advanced Research and Development Authority/Partner Therapeutics; HLA-DR LDT - Biomedical Advanced Research and Development Authority/Partner TherapeuticsLatest Information Update: 03 Nov 2021
Price :
$50
*
At a glance
- Originator Covance; Partner Therapeutics
- Developer Biomedical Advanced Research and Development Authority; Partner Therapeutics
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Sepsis
Highest Development Phases
- Preclinical Sepsis
Most Recent Events
- 20 Oct 2021 Partner Therapeutics and Labcorp Drug Development plans two clinical trials in Sepsis (In Adults, in Adolscents, In children)
- 20 Sep 2021 Biomedical Advanced Research and Development Authority, Labcorp Drug Development and Partner Therapeutics and for the development of sargramostim companion diagnostic
- 20 Sep 2021 Sargramostim companion diagnostic is available for licensing as of 20 Sep 2021. http://www.partnertx.com